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Accumulation of amyloid-β peptide (Aβ) appears to contribute to the pathogenesis of Alzheimer’s disease (AD). Therapeutic hope
for the prevention or removal of Aβ deposits has been placed in strategies involving immunization against the Aβ peptide. Initial
Aβ immunization studies in animal models of AD showed great promise. However, when this strategy was attempted in human
subjects with AD, an unacceptable degree of meningoencephalitis occurred. It is generally believed that this adverse outcome
resulted from a T-cell response to Aβ. Speciﬁcally, CD4
+ Th1 and Th17 cells may contribute to severe CNS inﬂammation and
limit the utility of Aβ immunization in the treatment of AD. Interleukin (IL)-12 and IL-23 play critical roles in the development
of Th1 and Th17 cells, respectively. In the present study, Aβ1-42 synergistically elevated the expression of IL-12 and IL-23 triggered
by inﬂammatory activation of microglia, and the peroxisome proliferator-activated receptor (PPAR)-γ agonist 15-deoxy-Δ12,14-
PGJ2 (15d-PGJ2)e ﬀectively blocked the elevation of these proinﬂammatory cytokines. Furthermore, 15d-PGJ2 suppressed the Aβ-
related synergistic induction of CD14, MyD88, and Toll-like receptor 2, molecules that play critical roles in neuroinﬂammatory
conditions. Collectively, these studies suggest that PPAR-γ agonists may be eﬀective in modulating the development of AD.
Copyright © 2008 Jihong Xu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder
and the most common cause of dementia in the elderly.
AD is characterized by progressive memory deﬁcits, changes
in personality, and cognitive decline. It is believed that
abnormal accumulation of amyloid-β peptide (Aβ), either as
a soluble factor or as extracellular aggregates, contributes to
thedevelopmentofAD[1–3].Cleavageofamyloidprecursor
protein (APP) can produce amyloid-β peptide 1-42 (Aβ1-42),
the levels of which are correlated with neurotoxicity and
development of AD. The connection between Aβ and AD
symptomsisfurtherstrengthenedbymousemodelsinwhich
transgenic expression of the human Aβ precursor (APP)
results in accumulation of Aβ and deﬁcits in memory tests
[4]. Preclinical investigations of anti-Aβ therapies have come
to rely on such mice as a loose approximation of AD
pathogenesis. The most successful anti-Aβ strategy demon-
strated in these mice to date involves recruiting the immune
system through vaccination. APP-transgenic mice that are
immunized againstAβ at a young age never develop substan-
tial Aβ deposits, and vaccination after deposition can even
reverse a signiﬁcant degree of the Aβ accumulation [5]. Most
importantly, behavioral deﬁcits are alleviated by such immu-
nizations. These beneﬁts correlate strongly with the titers
of soluble antibody generated against Aβ [6–8], and passive
immunization by injection of anti-Aβ antibody alone is also
eﬀective [9, 10]. Unfortunately, the ﬁrst attempt to translate
this vaccination approach to human AD patients generated
iatrogenic meningoencephalitis in about 6% of individuals
[11]. Mice can be induced to undergo similar reactions
whenoverexpressinginterferon(IFN)-γ [12],suggestingthat
immuneresponsestiltedinfavorofTh1responsesfostercell-
mediated and/or inﬂammatory reactions to the vaccination.
There is a considerable elaboration of inﬂammatory index in
a l lA Db r a i n s[ 13, 14], including the activation of microglia;2 PPAR Research
apparently, this neuroinﬂammation is fostered by Aβ itself
[15, 16]. It is possible that these proinﬂammatory actions
of Aβ create conditions unfavorable for the development of
humoral immune responses.
IL-12 family cytokines are heterodimeric proteins which
include IL-12 and IL-23. IL-12 is composed of p40 and p35
subunits, and IL-23 is composed of the same p40 subunit
together with a unique p19 subunit [17]. IL-12 plays a
critical role in the diﬀerentiation of CD4+ Th1 lymphocytes.
These Th1 lymphocytes stimulate cell-mediated immune
responses important in clearing pathogens, including viruses
and bacteria. Th1 lymphocytes produce IFN-γ which acti-
vates cells of the innate immune system and contributes
to the clearance of these pathogens. IL-23 stimulates the
diﬀerentiationofauniquesetofCD4+ Tlymphocytes.These
cells are characterized by the production of the cytokine IL-
17 and are termed as Th17 lymphocytes [18]. Recent studies
indicated that mice genetically ablated of the p19 subunit
of IL-23 are resistant to the development of experimental
autoimmune encephalomyelitis (EAE), whereas mice lacking
the p35 subunit of IL-12 showed similar or more severe
EAE than that observed in wild-type animals [19–21]. It
thus appears that IL-12 and IL-23 each play important yet
distinct roles in the development of immune responses that
tend towards cell-mediated modalities which can include
inﬂammation. Thus, suppressing the production of these
cytokines may be eﬀective in the treatment of inﬂammatory
diseases.
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor family of tran-
scriptional activators. Three PPAR subtypes exist (PPAR-α,
PPAR-γ, and PPAR-β/δ), each exhibiting distinct patterns of
tissue expression and ligand speciﬁcities [22] .T h er o l eo f
PPAR-γ in modulating adipogenesis and glucose metabolism
is well established. Thiazolidinediones are PPAR-γ agonists
that are currently used extensively in the treatment of
type II diabetes. More recently, the role of PPAR-γ ago-
nists in modulating immune responses, including immune
responses in the CNS, has become appreciated. Nonsteroidal
anti-inﬂammatory drugs (NSAIDs) have been shown to
reduce AD risk and ameliorate microglial reactivity in AD
brains [23]. Since NSAIDs bind to and activate PPAR-γ,
resulting in reduced expression of proinﬂammatory genes,
this receptor may mediate the observed anti-inﬂammatory
eﬀects of NSAIDs in AD brain. In addition, it has been
demonstrated that the PPAR-γ agonists, pioglitazone and
ibuprofen, reduced glial inﬂammation and Aβ1-42 levels in
APPV717I transgenic mice [24]. Collectively, these studies
suggest that PPAR-γ agonists may be eﬀective in the treat-
ment of neurodegenerative diseases, including AD.
Pattern recognition receptors termed as Toll-like recep-
tors(TLRs)playacriticalroleintheinnateimmuneresponse
to pathogen-associated molecular patterns (PAMPs) present
in viruses, bacteria, and fungi [25]. They may also contribute
to neuroinﬂammation triggered by endogenous ligands [25]
or simply overexpression of the receptors alone [26]. A
series of eleven TLRs have been identiﬁed in mice and
humans, each capable of binding distinct PAMPs. The PAMP
lipopolysaccharide (LPS) binds to TLR4 in association with
another pattern recognition receptor termed as CD14. With
the exception of TLR3, ligand binding to TLRs stimulates
recruitment of the adaptor molecule MyD88, activating a
well-deﬁned signal transduction pathway that culminates in
activation of the transcription factor NF-κB, which elevates
expression of a variety of proinﬂammatory genes [27].
TLR4 has been suggested to play a role in regulating the
pathogenesis of AD in humans [28, 29] and in animal
models of AD [30]. This suggests that agents capable of
altering MyD88-dependent TLR signaling may modulate the
development of AD.
ThecurrentstudiesindicatethatthePPAR-γ agonist15d-
PGJ2 suppresses the production of IL-12 and IL-23 by Aβ
plus LPS-stimulated microglia. These cytokines play critical
roles in Th1 and Th17 cell diﬀerentiation. These studies
could have important implications concerning Aβ immu-
nization as therapy for AD. In addition, we demonstrate that
15d-PGJ2 inhibitsAβ plusLPSstimulationofMyD88,CD14,
and TLR2 expression by microglia, suggesting that this
cyclopentenone prostaglandin inhibits MyD88-dependent
signaling. This provides a potential mechanism by which
the PPAR-γ agonist 15d-PGJ2 modulates the expression of
proinﬂammatory cytokines.
2. MATERIALS AND METHODS
2.1. Reagents
15d-PGJ2 was obtained from Cayman Chemical Company
(Ann Arbor, Mich, USA). Lipopolysaccharide and lectin,
Griﬀonia simplicifolia, were obtained from Sigma (St. Louis,
Mo, USA). Aβ1-42 was obtained from AnaSpec, Inc. (San
Jose, Calif, USA). DMEM media, glutamine, trypsin, and
antibiotics used for tissue culture were obtained from
BioWhittaker (Walkersville, Md, USA). OPI medium sup-
plement was obtained from Sigma. Fetal bovine serum
(FBS) was obtained from Hyclone (Logan, Utah, USA). GM-
CSF was obtained from BD Pharmingen (San Diego, Calif,
USA). N-2 supplement was obtained from Gibco Invitrogen
Corporation (Carlsbad, Calif, USA). Glial ﬁbrillary acidic
protein (GFAP) was obtained from Dako (Carpinteria,
Calif, USA). C57BL/6 mice were obtained from Harlan
(Indianapolis, Ind, USA) and bred in house.
2.2. Cellculture
Primary mouse microglia cultures were obtained through
a modiﬁcation of the McCarthy and deVellis protocol [31].
Brieﬂy, cerebral cortices from 1–3 day-old C57BL/6 mice
were excised, meninges removed, and cortices minced into
small pieces. Cells were separated by trypsinization followed
by trituration of cortical tissue. The cell suspension was
ﬁltered through a 70μmc e l ls t r a i n e rt or e m o v ed e b r i s .C e l l s
were centrifuged at 153 × gf o r5 m i n u t e sa t4 ◦C, resus-
pended in DMEM medium containing 10% FBS, 1.4mm
L-glutamine, 100U/mL penicillin, 0.1mg/mL streptomycin,
OPI medium supplement, and 0.5ng/mL recombinant
mouse GM-CSF, and plated into tissue culture ﬂasks. Cells
w e r ea l l o w e dt og r o wt oc o n ﬂ u e n c y( 7 – 1 0d a y s )a t3 7 ◦C/5%Jihong Xu et al. 3
CO2. Flasks were then shaken overnight (200rpm at 37◦C)
in a temperature-controlled shaker to loosen microglia and
oligodendrocytes from the more adherent astrocytes. These
less adherent cells were plated for 2-3 hours and then lightly
shaken to separate oligodendrocytes from the more adherent
microglia. Microglia were seeded in 24-well plates or 6-
well plates and incubated overnight at 37◦C/5% CO2.A f t e r
overnight incubation, cells were treated with 15d-PGJ2 for
1 hour in the serum free medium with N-2 supplement,
and then stimulated with Aβ1-42 and/or LPS for 6 or 24
hours. Aβ1-42 peptides were dissolved in DMSO to prepare
a 5mM stock solution, which was aliquoted and stored
at −80◦C. Aβ1-42 stock solution was diluted with culture
medium to a concentration of 0.1mM, and set at room
temperature for 12–18 hours before use. The ﬁnal applied
concentration of DMSO from Aβ1-42 was ≤0.2%. After
the 24-hour stimulation, tissue culture supernatants were
collected for enzyme-linked immunosorbent assay (ELISA),
and cell viability was analyzed; 6 hours after stimulation,
total RNA was collected for real-time quantitative RT-PCR
(qRT-PCR) analysis. The purity of microglia cultures was
greater than 95% as determined by immunohistochemical
staining with the lectin, Griﬀonia simplicifolia.A s t r o c y t e
contamination of the microglial cultures was assessed by
immunohistochemical staining with anti-GFAP.
2.3. Cellviabilityassay
Cell viability was determined by MTT reduction assay as
described previously [32]. Optical densities were determined
using a Spectromax 190 microplate reader (Molecular
Devices, Sunnyvale, Calif, USA) at 570nm. Results were
reported as percent viability relative to untreated cultures.
2.4. Enzyme-linkedimmunosorbentassay(ELISA)
Cytokine (IL-12p40, IL-12p70, and IL-1β)l e v e l si nt i s s u e
culture media were determined by ELISA as described by
the manufacturer (OptEIA Sets, Pharmingen, San Diego,
Calif, USA). Cytokine IL-23 (p19/p40) levels in tissue
culture media were determined by ELISA as described by
the manufacturer (eBioscience, San Diego, Calif, USA).
Optical densities were determined using a Spectromax 190
microplate reader (Molecular Devices, Sunnyvale, Calif,
USA) at 450nm. Cytokine concentrations in media were
determined from standards containing known concentra-
tions of the proteins.
2.5. RNAisolationandcDNAsynthesis
Total RNA was isolated from microglia using the RNeasy
Mini Kit (Qiagen Sciences, Md, USA). RNA samples were
treated with DNAse1 (Invitrogen, Carlsbad, Calif, USA)
to remove any traces of contaminating DNA. The reverse
transcription (RT) reactions were carried out using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, Calif, USA)
according to the manufacturer’s instructions.
2.6. Real-timequantitativeRT-PCRassay
IL-12p40, IL-12p35, IL-23p19, IL-1β, CD14, MyD88, TLR2,
and TLR4 mRNAs were quantiﬁed by real-time PCR using
an iCycler IQ multicolor real-time PCR detection system
(Bio-Rad). All primers and TaqMan MGB probes (FAMdye-
labeled) were designed and synthesized by Applied Biosys-
tems (Foster City, Calif, USA). The real-time PCR reactions
were performed in a total volume of 25μL using an iCycler
kit (Bio-Rad). The levels of IL-12p40, IL-12p35, IL-23p19,
IL-1β, CD14, MyD88, TLR2, and TLR4 mRNA expression
in primary microglia were calculated after normalizing cycle
thresholds against the “housekeeping” gene GAPDH, and
are presented as the fold induction value (2−ΔΔCt)r e l a t i v et o
LPS-stimulated microglia.
2.7. Statistics
Data were analyzed by one-way ANOVA followed by a
Bonferroni posthoc test to determine the signiﬁcance of
diﬀerence.
3. RESULTS
3.1. Effectsof15d-PGJ2 onIL-1βproductionby
β-amyloidplusLPS-stimulatedmicroglia
A variety of studies suggest that the inﬂammatory cytokine
IL-1β plays a signiﬁcant role in modulating the pathogenesis
of AD [33]. In the present study, we investigated whether
Aβ1-42 plus a low dose of LPS could induce IL-1β production
by primary mouse microglial cells. Our results showed that
Aβ1-42 alone did not induce microglia production of IL-1β
protein (Figure 1(a))a n dI L - 1 β mRNA (Figure 1(b)). LPS
(10ng/mL) alone stimulated microglial production of IL-
1β protein and mRNA, while a combination of Aβ1-42 and
LPS synergistically induced the expression of IL-1β protein
and mRNA. Interestingly, the PPAR-γ agonist 15d-PGJ2
strongly suppressed induction of IL-1β in Aβ1-42 plus LPS-
stimulated primary microglial cells. The PPAR-γ agonist did
not decrease the viability of these microglial cells compared
to cells treated with Aβ1-42 plus LPS as determined by MTT
analysis (data not shown). Therefore, the eﬀects of 15d-PGJ2
on the production of IL-1β were not due to eﬀects on cell
viability. These studies suggest that 15d-PGJ2 may suppress
the production of IL-1β, an inﬂammation-related cytokine
associated with the pathogenesis of AD.
3.2. Effectsof15d-PGJ2 onIL-12familycytokinesby
β-amyloidplusLPS-stimulatedmicroglia
IL-12 family cytokines are believed to contribute to the
diﬀerentiation of Th1 and Th17 cells. Aβ1-42 alone had little
or no eﬀect on the production of IL-12 family cytokines by
microglia. LPS (10ng/mL) stimulated microglia to secrete
IL-12 family cytokines including IL-12p40 (Figure 2(a)), IL-
12p70 (Figure 2(b)), and IL-23 (Figure 2(c)). In the context
of this inﬂammatory priming, Aβ1-42 further increased
microglial production of each of these IL-12 family proteins
signiﬁcantly. Furthermore, the PPAR-γ agonist 15d-PGJ24 PPAR Research
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Figure 1: 15d-PGJ2 inhibits IL-1β expression by Aβ1-42 plus LPS-activated microglia. (a) Primary mouse microglial cells were pretreated for 1
hour with 15d-PGJ2 (2.5μM). Aβ1-42 (5μM), LPS (10ng/mL), or Aβ1-42 (5μM) plus LPS (10ng/mL) was added as indicated, and 24 hours
later, the concentration of IL-1β in the culture medium was determined. Values represent the mean ± s.e.m for a representative experiment
run in triplicate. At least three independent experiments were conducted. (b) Cells were pretreated for 1 hour with 15d-PGJ2 (2.5μM).
Aβ1-42 (10μM), LPS (5ng/mL), or Aβ1-42 (10μM) plus LPS (5ng/mL) was added as indicated, and 6 hours later, total RNA was isolated.
IL-1β mRNA levels were determined by real-time quantitative RT-PCR. Results are expressed as fold inductions in GAPDH normalized
mRNA values versus levels in LPS-treated cells. Values are mean ± s.e.m of six samples derived from three independent experiments, with
each experiment performed in duplicate. ∗∗P<. 01 and ∗∗∗P<. 001 versus Aβ1-42 + LPS-treated cultures.
signiﬁcantly suppressed the expression of these IL-12 family
proteins.
3.3. Effectsof15d-PGJ2 onexpressionofIL-12family
cytokinesubunitmRNAsbyβ-amyloidplus
LPS-stimulatedmicroglia
Aβ1-42 alone had little or no eﬀect on stimulating the expres-
sion of IL-12 family cytokine subunit mRNAs including IL-
12p35 (Figure 3(a)), IL-12p40 (Figure 3(b)), and IL-23p19
(Figure 3(c)). Low doses of LPS (5ng/mL) alone slightly
induced the expression of these mRNAs. However, Aβ1-42
in combination with LPS elicited signiﬁcantly higher levels
of IL-12 family subunit mRNAs compared to microglia
stimulated with LPS alone. Pretreatment with 15d-PGJ2
signiﬁcantly suppressed the expression of IL-12 family
subunit mRNAs. Thus, 15d-PGJ2 inhibits the expression
of IL-12 family cytokines and the mRNAs that encode
these proteins. IL-12 and IL-23 play critical roles in the
diﬀerentiation of Th1 and Th17 cells, which may contribute
to the inﬂammatory events that resulted in cessation of
clinical trials involving immunization of Aβ in the treatment
of AD. Thus, cotreatment with 15d-PGJ2 may increase the
utility of Aβ immunotherapy for AD patients.
3.4. Effectsof15d-PGJ2 onexpressionofToll-like
receptorsignaling
The MyD88-dependent TLR signaling pathway plays a
critical role in modulating the response to PAMPs including
LPS. We demonstrate that a combination of Aβ1-42 plus
LPS signiﬁcantly induced the expression of CD14 relative to
microglia treated with LPS alone (Figure 4(a)). In addition,
Aβ1-42 plus LPS also trended towards inducing MyD88
expression relative to each stimulus alone (Figure 4(b)).
CD14 and MyD88 are critical intermediates in MyD88-
dependent signaling. As we have demonstrated previously,
LPSdoesnotsigniﬁcantlyinducetheexpressionofTLR4,but
does induce the expression of TLR2 [34]. Similarly, Aβ1-42 in
combination with LPS did not induce microglial expression
of TLR4 (Figure 4(c)), but did induce the expression of
TLR2 (Figure 4(d)). Interestingly, 15d-PGJ2 inhibited Aβ1-42
plus LPS induction of MyD88, CD14, and TLR2 mRNA
expression in microglia. These studies suggest that 15d-PGJ2
may suppress inﬂammatory responses stimulated by Aβ1-42
plus LPS by inhibiting MyD88-dependent TLR signaling.
4. DISCUSSION
AD currently aﬀects over 200 million people worldwide.
Disease incidence is expected to increase as the population
ages, and the socioeconomic impact of AD is staggering.
The disease is characterized in part by the presence of
neuritic plaques which contain accumulations of insoluble
Aβ. Vaccination with Aβ synthetic peptides in animal
models of AD suggested that such immunizations may be
eﬀective in the treatment of AD in humans. For example,
Aβ immunization of APP transgenic mice decreases the
density and number of Aβ deposits in the brains of these
mice. Decreased Aβ deposits in these mice are associated
with decreased neuritic dystrophy and gliosis [7]. Intranasal
administration of Aβ engenders humoral responses that
include immunoglobulin isotypes consistent with a Th2
response, and this is associated with increased clearance
of amyloid [35]. Signiﬁcantly, active immunization against
Aβ in APP transgenic mice decreases memory deﬁcits inJihong Xu et al. 5
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Figure 2: 15d-PGJ2 inhibits IL-12 family cytokines production by
Aβ1-42 plus LPS-activated microglia. Cells were pretreated for 1 hour
with 15d-PGJ2 (2.5μM). Aβ1-42 (5μM), LPS (10ng/mL), or Aβ1-42
(5μM) plus LPS (10ng/mL) was added as indicated, and 24 hours
later, the concentration of IL-12p40 (a), IL-12p70 (p35/p40) (b),
and IL-23 (p19/p40) (c) in the culture medium was determined.
Values represent the mean ± s.e.m for a representative experiment
run in triplicate. At least three independent experiments were
conducted. ∗∗P<. 01 and ∗∗∗P<. 001 versus Aβ1-42 + LPS-treated
cultures.
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Figure 3: 15d-PGJ2 inhibits microglial mRNA expression of IL-
12p40, IL-12p35, and IL-23p19 induced by Aβ1-42 plus LPS.C e l l s
were pretreated for 1 hour with 15d-PGJ2 (2.5μM). Aβ1-42 (10μM),
LPS (5ng/mL), or Aβ1-42 (10μM) plus LPS (5ng/mL) was added
as indicated, and 6 hours later, total RNA was isolated. IL-12p35
(a), IL-12p40 (b), and IL-23p19 (c) mRNA levels were determined
by real-time quantitative RT-PCR. Results are expressed as fold
inductions in GAPDH normalized mRNA values versus levels
in LPS-treated cells. Values are mean ± s . e . mo fs i xs a m p l e s
derived fromthree independent experiments, witheach experiment
performed in duplicate. ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001
versus Aβ1-42 + LPS-treated cultures.6 PPAR Research
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Figure 4: The eﬀects of 15d-PGJ2 on microglial mRNA expression of CD14, MyD88, TLR4, and TLR2 induced by Aβ1-42 plus LPS.C e l l sw e r e
pretreated for 1 hour with 15d-PGJ2 (2.5μM). Aβ1-42 (10μM), LPS (5ng/mL), or Aβ1-42 (10μM) plus LPS (5ng/mL) was added as indicated,
and 6 hours later, total RNA was isolated. CD14 (a), MyD88 (b), TLR4 (c), and TLR2 (d) mRNA levels were determined by real-time
quantitative RT-PCR. Results are expressed as fold inductions in GAPDH normalized mRNA values versus levels in LPS-treated cells. Values
are mean ± s.e.m of six samples derived from three independent experiments, with each experiment performed in duplicate. ∗P<. 05,
∗∗P<. 01, and ∗∗∗P<. 001 versus Aβ1-42 + LPS-treated cultures.
these mice [6, 35, 36]. Interestingly, passive administration
of monoclonal antibodies speciﬁc for Aβ peptides is also
eﬀective in clearing Aβ and improving memory deﬁcits in
APP transgenic mice [37, 38]. This suggests that Aβ-speciﬁc
antibodies produced following immunization are the critical
factor mediating AD-like pathology in these animal models
of AD. Three potential mechanisms have been suggested that
may determine how anti-Aβ antibodies reduce Aβ deposits
in the brains of APP transgenic mice. Aβ antibodies (1) may
directly dissolve Aβ deposits, (2) may stimulate Fc-receptor-
mediated phagocytosis of Aβ by microglia, and/or (3) may
stimulate Aβ eﬄux from the brain to the plasma [3].
Animal studies indicating that Aβ immunization of APP
transgenic mice reduced plaque burden in mice stimulated
human clinical trials designed to evaluate the clinical eﬃcacy
of Aβ immunization in the treatment of AD. Small-scale
phase I trials indicated apparent safety of Aβ immunization,
and demonstrated that the majority of mild to moderate
AD patients immunized in these studies produced anti-Aβ
antibodies [39, 40]. However, subsequent larger-scale phase
II clinical trials were halted when approximately 6% of Aβ
immunized patients developed meningoencephalitis [11].
Postmortem evaluation indicated that Aβ immunization
resulted in decreased plaque burden in the cortex of treated
patients [41–43], and these brain regions were associated
with abundant Aβ immunoreactive microglia, suggesting
that these cells were involved in the removal of Aβ [43].
Interestingly, although anti-Aβ antibodies are believed to
contribute to the reduction in Aβ plaques in AD patients,
antibodies titers did not correlate with the development of
meningoencephalitis [11, 40]. Several studies suggest that T
cell responses to Aβ may have stimulated the development
of meningoencephalitis in immunized AD patients [44–46].
Furthermore, a higher T cell reactivity to Aβ has been
observed in some elderly and AD patients not immunized
with Aβ. This suggests that the elderly population and ADJihong Xu et al. 7
patients may exhibit increased susceptibility to the develop-
ment of meningoencephalitis following Aβ vaccination [46].
Cases of meningoencephalitis were associated with increased
inﬁltration of both CD4+ and CD8+ T cells [42]. However,
it is generally believed that CD4+ Th1 cells triggered the
development of meningoencephalitis following Aβ immu-
nization [3]. The potential role of the recently described
CD4+Th17 cells in the production of meningoencephalitis
has not been evaluated. However, studies indicating that
these cells play a critical role in the development of MS and
other autoimmune disorders suggest that these cells may also
play a role in the development of meningoencephalitis in Aβ
immunized AD patients.
Our current studies indicate that the PPAR-γ agonist
15d-PGJ2 inhibits microglial production of IL-12 and IL-
23, which play critical roles in the diﬀerentiation of Th1
and Th17 cells, respectively. This suggests that 15d-PGJ2
could potentially increase the eﬃcacy and safety of Aβ
immunization of AD patients by decreasing or abolishing
the development of meningoencephalitis in these patients.
Epidemiological studies indicated that nonsteroidal anti-
inﬂammatory drugs (NSAIDs) reduced the risk of AD. Some
NSAIDs are capable of activating PPAR-γ, suggesting that
these drugs may modulate development of AD through
activation of this receptor [47, 48]. The role of PPAR-
γ in modulating AD is supported by studies indicating
that ibuprofen reduced Aβ1-42 levels in APP transgenic
mouse models of AD, while low levels of the thiazo-
lidinedione pioglitazone stimulated a slight yet statistically
insigniﬁcant reduction of Aβ1-42 levels in these mice [49].
In a later study, higher levels of pioglitazone decreased
astrocyte and microglial activation and Aβ plaque burden
in APP transgenic mice [24]. Similarly, the thiazolidinedione
rosiglitazone also decreased Aβ1-42 levels in animal models
of AD [50]. Collectively, these studies support a role for
PPAR-γ in modulating AD pathology. Studies indicate that
PPAR-γ activation suppresses expression of β-site of APP
cleaving enzyme (BACE)-1, suggesting that PPAR-γ agonists
may modulate AD pathogenesis at least in part by altering
Aβ homeostasis [51]. Importantly, recent clinical studies
demonstrated that rosiglitazone was eﬀective in improving
cognition in a subset of AD patients [52, 53]. The fact that
rosiglitazone exhibits poor blood-brain barrier penetration
suggests that this PPAR-γ agonist may act in the periphery
and not directly in the CNS.
We and others have previously demonstrated that PPAR-
γ agonists are capable of suppressing the activation of NF-
κB, which is a potent transcriptional activator of a variety
of genes encoding proinﬂammatory molecules. MyD88-
dependent signaling results in the activation of NF-κB. In
the current studies, we demonstrate that the PPAR-γ agonist
15d-PGJ2 suppressed microglial expression of MyD88 and
CD14 which are critical intermediates in MyD88-dependent
TLR signaling. In addition, we demonstrate that 15d-PGJ2
inhibits microglial expression of IL-1β, a cytokine believed
to contribute to AD pathogenesis [33]. Thus, PPAR-γ
agonists may act as general suppressors of classical activation
of microglia. Since classically activated microglia produce
neurotoxic molecules, suppression of microglial activation
may protect against AD. However, it should also be noted
that some form of microglial activation may help remove Aβ
plaques from AD brains through phagocytosis. In addition,
TLR and CD14 molecules have been suggested to contribute
to—or alternatively protect against—the development of AD
[30, 54, 55]. It clearly appears that microglia and microglial
products modulate AD through a series of complex and
potentially conﬂicting mechanisms.
In summary, we have demonstrated that the PPAR-γ
agonist 15d-PGJ2 inhibits production of IL-12 and IL-23 by
Aβ plus LPS-activated microglia. These cytokines regulate
the diﬀerentiation of Th1 and Th17 cells, which may limit
the eﬃcacy of Aβ immunotherapy for the treatment of AD.
Furthermore, we demonstrate that 15d-PGJ2 inhibits the
production of IL-1β by microglia, a cytokine known to play
a role in AD pathogenesis. Finally, we demonstrate that 15d-
PGJ2 inhibits the expression of MyD88-dependent signaling
intermediates, suggesting a mechanism by which this PPAR-
γ agonist may suppress inﬂammation. Collectively, these
studies contribute to the body of evidence indicating that
PPAR-γ agonists may be eﬀective in the treatment of AD.
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